GlycoSeLect opens Equity Raising Round for Irish Investors
Eligible Investors in the round can avail of tax relief up to 40% against Total Income under the Employment & Investment Incentive Scheme (EIIS) as part of their investment in qualifying Small and Medium Enterprises (SMEs).
This finance round will facilitate further investment and grants to develop our RPL technology in biopharmaceutical manufacturing, especially vaccine and cancer immunotherapy applications.
For more information on this investment opportunity, please contact our CEO, Robert Dunne, by email robert.dunne@glycoselect.com or Tel 01 2544164, Mobile 087 790265.